Centene reported a 36% decline in net income year-over-year, along with major growth in exchange enrollment, according to its third-quarter earnings posted Oct. 24.
"Our strong third quarter results demonstrate the positive momentum Centene is generating as we prepare for 2024. Marketplace growth, effective navigation of redeterminations year-to-date and successful execution against value creation initiatives together position us well to continue advancing our strategic priorities," CEO Sarah London said.
Total revenues in the third quarter were more than $38 billion, up 6.1% year over year.
Total net earnings in the third quarter were $469 million, down 36% since the same period last year.
The company raised its year-end adjusted EPS guidance to at least $6.60. Year-end revenues are projected to range between $149 billion and $151 billion.
The company's medical loss ratio was 87% in the third quarter and 88.3% during the same period last year. Days claims payable were 53 in the third quarter, compared to 52 a year ago.
As of Sept. 30, Centene's total membership stands at nearly 28 million. Medicaid membership has fallen to 15.2 million since the first quarter, decreasing 6.6%. There are nearly 3.7 million exchange members, 424,000 commercial group members, 1.3 million Medicare Advantage and supplement members, and 4.5 million Medicare prescription drug plans. Medicaid and Medicare membership totals include 1.3 million D-SNP plans.